MX2021014189A - Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas. - Google Patents
Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas.Info
- Publication number
- MX2021014189A MX2021014189A MX2021014189A MX2021014189A MX2021014189A MX 2021014189 A MX2021014189 A MX 2021014189A MX 2021014189 A MX2021014189 A MX 2021014189A MX 2021014189 A MX2021014189 A MX 2021014189A MX 2021014189 A MX2021014189 A MX 2021014189A
- Authority
- MX
- Mexico
- Prior art keywords
- infectious diseases
- administration
- treating cancer
- dosing regimens
- 15rî2é
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La presente invención proporciona regímenes de administración cíclica en pulsos y regímenes de administración en pulsos para agonistas del receptor ß? de la interleucina-2/interleucina-15 (IL-2/IL-15Rß?) para tratar o gestionar el cáncer o las enfermedades infecciosas en pacientes humanos. Los regímenes de administración incluyen, entre otras cosas, la administración diaria de agonistas de IL-2/IL-15Rß? durante 2, 3 o 4 días consecutivos, seguidos de días sin administración.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19175436 | 2019-05-20 | ||
EP19177064 | 2019-05-28 | ||
PCT/EP2020/064132 WO2020234387A1 (en) | 2019-05-20 | 2020-05-20 | IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014189A true MX2021014189A (es) | 2022-01-06 |
Family
ID=70802860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014189A MX2021014189A (es) | 2019-05-20 | 2020-05-20 | Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220241375A1 (es) |
EP (1) | EP3972629A1 (es) |
JP (1) | JP2022533222A (es) |
KR (1) | KR20220012296A (es) |
AU (1) | AU2020279534A1 (es) |
CA (1) | CA3136241A1 (es) |
IL (1) | IL288210A (es) |
MX (1) | MX2021014189A (es) |
SG (1) | SG11202111409YA (es) |
WO (1) | WO2020234387A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4232068A1 (en) * | 2020-10-26 | 2023-08-30 | Cytune Pharma | IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
JP2023550685A (ja) * | 2020-10-26 | 2023-12-05 | サイチューン ファーマ | 扁平上皮癌を治療するためのIL-2/IL-15Rβγアゴニスト |
AU2022325498A1 (en) | 2021-08-13 | 2024-02-01 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
US7371371B2 (en) | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
WO2003048334A2 (en) | 2001-12-04 | 2003-06-12 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
ES2367027T3 (es) | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
US20060057680A1 (en) | 2004-08-11 | 2006-03-16 | Zheng Xin X | Mutant interleukin-15 polypeptides |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
AU2007271398B2 (en) | 2006-07-06 | 2013-06-20 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses |
DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
WO2009135031A1 (en) | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
LT3489255T (lt) | 2011-02-10 | 2021-08-25 | Roche Glycart Ag | Mutantiniai interleukino-2 polipeptidai |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
JP6359019B2 (ja) | 2012-10-24 | 2018-07-18 | ノバルティス アーゲー | IL−15Rα型、IL−15Rα型を発現する細胞、ならびにIL−15RαおよびIL−15/IL−15Rα複合体の治療上の使用 |
KR102561553B1 (ko) | 2013-03-15 | 2023-07-31 | 젠코어 인코포레이티드 | 이형이량체 단백질 |
US10202433B2 (en) | 2013-06-27 | 2019-02-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | IL-15 mutant polypeptides as IL-15 antagonists and encoding nucleic acids |
EP4269441A3 (en) * | 2013-08-08 | 2024-01-24 | Cytune Pharma | Il-15 and il-15ralpha sushi domain based on modulokines |
DK3030262T3 (da) * | 2013-08-08 | 2019-12-02 | Cytune Pharma | Kombineret farmaceutisk sammensætning |
CN105189562B (zh) | 2014-01-08 | 2019-08-16 | 上海恒瑞医药有限公司 | Il-15异源二聚体蛋白及其用途 |
PL3094351T3 (pl) | 2014-01-15 | 2022-06-27 | Kadmon Corporation, Llc | Środki immunomodulujące |
CN107001438A (zh) | 2014-10-14 | 2017-08-01 | 阿尔莫生物科技股份有限公司 | 白细胞介素‑15组合物及其用途 |
EP3064507A1 (en) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
CN112574316A (zh) | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
JP6800219B2 (ja) | 2015-09-16 | 2020-12-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 特異的なインターロイキン−15(il−15)アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用 |
JP2018532729A (ja) | 2015-09-25 | 2018-11-08 | アルター・バイオサイエンス・コーポレーション | インターロイキン−15スーパーアゴニストは、移植片対腫瘍活性を大幅に増強する |
EP3393486A4 (en) | 2015-12-21 | 2019-09-11 | Armo Biosciences, Inc. | INTERLEUKIN-15 COMPOSITIONS AND USES THEREOF |
JP7142630B2 (ja) | 2016-10-14 | 2022-09-27 | ゼンコア インコーポレイテッド | IL15/IL15Rαヘテロ二量体FC-融合タンパク質 |
NZ753515A (en) | 2016-11-30 | 2022-02-25 | Oncomed Pharm Inc | Methods for treatment of cancer comprising tigit-binding agents |
EP3570870A1 (en) * | 2017-01-20 | 2019-11-27 | Novartis AG | Combination therapy for the treatment of cancer |
BR112019017001A2 (pt) | 2017-02-16 | 2020-04-28 | Sonnet Bio Therapeutics | composição, proteína de fusão, ácido nucleico, célula hospedeira, e, métodos para produção de um domínio de aglutinação de albumina, para preparação de uma variante de il-15, para produção de uma proteína de fusão e para inibição ou redução de um tumor em um indivíduo em necessidade do mesmo. |
JP7316222B2 (ja) | 2017-05-15 | 2023-07-27 | ネクター セラピューティクス | 長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法 |
TWI757528B (zh) | 2017-08-03 | 2022-03-11 | 美商欣爍克斯公司 | 用於增生及感染性疾病治療之細胞激素結合物 |
KR20200127207A (ko) | 2018-02-26 | 2020-11-10 | 신톡스, 인크. | Il-15 접합체 및 이의 용도 |
EP3762422A1 (en) | 2018-03-08 | 2021-01-13 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
-
2020
- 2020-05-20 JP JP2021569017A patent/JP2022533222A/ja active Pending
- 2020-05-20 WO PCT/EP2020/064132 patent/WO2020234387A1/en unknown
- 2020-05-20 KR KR1020217041760A patent/KR20220012296A/ko unknown
- 2020-05-20 AU AU2020279534A patent/AU2020279534A1/en active Pending
- 2020-05-20 EP EP20727619.7A patent/EP3972629A1/en active Pending
- 2020-05-20 CA CA3136241A patent/CA3136241A1/en active Pending
- 2020-05-20 MX MX2021014189A patent/MX2021014189A/es unknown
- 2020-05-20 US US17/612,432 patent/US20220241375A1/en active Pending
- 2020-05-20 SG SG11202111409YA patent/SG11202111409YA/en unknown
-
2021
- 2021-11-17 IL IL288210A patent/IL288210A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220012296A (ko) | 2022-02-03 |
SG11202111409YA (en) | 2021-12-30 |
EP3972629A1 (en) | 2022-03-30 |
JP2022533222A (ja) | 2022-07-21 |
AU2020279534A1 (en) | 2021-11-11 |
US20220241375A1 (en) | 2022-08-04 |
IL288210A (en) | 2022-01-01 |
CA3136241A1 (en) | 2020-11-26 |
WO2020234387A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014189A (es) | Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas. | |
PH12020500241A1 (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
MX2021009259A (es) | Conjugados de il-2 y metodos de uso del mismo. | |
PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
NZ766454A (en) | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
MX2021006912A (es) | Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas. | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
CR20230330A (es) | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso | |
JOP20220071A1 (ar) | سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra | |
MX2022014230A (es) | Conjugados de anticuerpo-farmaco que comprenden agonistas de sting. | |
MX2022002740A (es) | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. | |
WO2021081193A8 (en) | Methods of administration of il-2 receptor agonists | |
PH12020551018A1 (en) | Oral delivery of glp-1 peptide analogs | |
MX2020011817A (es) | Metodos para tratar el linfoma. | |
MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
CR20230507A (es) | Anticuerpos anti-il-2r agonistas y métodos de uso | |
MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2022011163A (es) | Conjugados de polipeptidos de interleucina-2 y sus usos. | |
MX2020005342A (es) | Compuestos de pirazolopiridinona. | |
MX2007009914A (es) | Uso de agonistas selectivos para el receptor-beta de estrogeno para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion. | |
BR112021016923A2 (pt) | Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits |